Parents need to know that this sequel to the zombie horror fest 28 Days Later is at least as scary and disturbing as the original. Extreme, graphic peril and violence are nonstop; sympathetic ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback